MedTrace Logo

An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma

NCT05873959 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2024-11-25

No results posted yet for this study

Summary

Humacyte provided HAVs as humanitarian aid to Ukraine. This retrospective observational study is designed to collect data from patients in whom the HAVs have already been implanted on a humanitarian basis between June 2022 and May 2023.

Conditions

  • Trauma
  • Trauma Injury
  • Trauma, Multiple
  • Trauma Blunt

Interventions

BIOLOGICAL

HAV implantation

HAVs already implanted under humanitarian aid program to repair or reconstruct arteries following an extremity life- or limb-threatening traumatic injury.

Sponsors & Collaborators

  • Humacyte, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2023-05-26
Completion
2024-01-15
FDA Drug
Yes

Countries

  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05873959 on ClinicalTrials.gov